

June 25, 2018

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer

Boulder, Colo., (June 23, 2018) – Array BioPharma Inc. (NASDAQ: ARRY) announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAFV600E-mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines of therapy. The confirmed overall response rate (ORR) was 48% and among the 17 patients who received only one prior line of therapy the ORR was 62%.

The triple combination was generally well-tolerated with no unexpected toxicities. The most common grade 3 or 4 adverse events seen in at least 10% of patients were fatigue (13%), anemia (10%), increased blood creatine kinase (10%) and increased aspartate aminotransferase (10%).

Ono Pharmaceutical Co., Ltd. (“ONO”) entered into the license agreement with Array BioPharma Inc. regarding encorafenib, a BRAF inhibitor and binimetinib, a MEK inhibitor in May 2017 and received rights to develop and commercialize both products in Japan and South Korea. In April 2018, ONO submitted applications for the manufacturing and marketing approval of both compounds in Japan for the indication of unresectable BRAF-mutant melanoma. Encorafenib and binimetinib are currently in two global Phase 3 clinical trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study) and BRAF-mutant colorectal cancer (BEACON CRC study) as a combination therapy.

Please click [here](#) for the press release distributed by Array BioPharma Inc.

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

Public_relations@ono.co.jp